このエントリーをはてなブックマークに追加
ID 67697
フルテキストURL
fulltext.pdf 1.73 MB
著者
Nishikori, Asami Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Nishimura, Midori Filiz Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Tomida, Shuta Center for Comprehensive Genomic Medicine, Okayama University Hospital Kaken ID researchmap
Chijimatsu, Ryota Center for Comprehensive Genomic Medicine, Okayama University Hospital
Ueta, Himawari Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Lai, You Cheng Department of Medical Biotechnology and Laboratory Science, Chang Gung University
Kawahara, Yuri Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Takeda, Yudai Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Ochi, Sayaka Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Haratake, Tomoka Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Ennishi, Daisuke Center for Comprehensive Genomic Medicine, Okayama University Hospital
Nakamura, Naoya Department of Pathology, Tokai University School of Medicine
Momose, Shuji Department of Pathology, Saitama Medical Center, Saitama Medical University
Sato, Yasuharu Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences ORCID Kaken ID researchmap
抄録
Idiopathic multicentric Castleman disease (iMCD) is a type of Castleman disease unrelated to the Kaposi sarcoma-associated herpesvirus/human herpesvirus type 8 (KSHV/HHV8) infection. Presently, iMCD is classified into iMCD-IPL (idiopathic plasmacytic lymphadenopathy), iMCD-TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), and iMCD-NOS (not otherwise specified). The most common treatment for iMCD is using IL-6 inhibitors; however, some patients resist IL-6 inhibitors, especially for iMCD-TAFRO/NOS. Nevertheless, since serum IL-6 levels are not significantly different between the iMCD-IPL and iMCD-TAFRO/NOS cases, cytokines other than IL-6 may be responsible for the differences in pathogenesis. Herein, we performed a transcriptome analysis of cytokine storm-related genes and examined the differences between iMCD-IPL and iMCD-TAFRO/NOS. The results demonstrated that counts per million of STAT2, IL1R1, IL1RAP, IL33, TAFAIP1, and VEGFA (P < 0.001); STAT3, JAK2, MAPK8, IL17RA, IL18, TAFAIP2, TAFAIP3, PDGFA, VEGFC, CXCL10, CCL4, and CXCL13 (P < 0.01); and STAT1, STAT6, JAK1, MAPK1, MAPK3, MAPK6, MAPK7, MAPK9, MAPK10, MAPK11, MAPK12, MAPK14, NFKB1, NFKBIA, NFKBIB, NFKBIZ, MTOR, IL10RB, IL12RB2, IL18BP, TAFAIP6, TNFAIP8L1, TNFAIP8L3, CSF2RBP1, PDGFB, PDGFC, and CXCL9 (P < 0.05) were significantly increased in iMCD-TAFRO/NOS. Particularly, upregulated IL33 expression was demonstrated for the first time in iMCD-TAFRO/NOS. Thus, inflammatory signaling, such as JAK-STAT and MAPK, may be enhanced in iMCD-TAFRO/NOS and may be a cytokine storm.
キーワード
idiopathic multicentric Castleman disease
cytokine storm
transcriptome analysis
発行日
2024
出版物タイトル
Journal of Clinical and Experimental Hematopathology
64巻
4号
出版者
Japanese Society for Lymphoreticular Tissue Research
開始ページ
297
終了ページ
306
ISSN
1346-4280
NCID
AA11556796
資料タイプ
学術雑誌論文
言語
英語
OAI-PMH Set
岡山大学
著作権者
© 2024 The Japanese Society for Lymphoreticular Tissue Research
論文のバージョン
publisher
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.3960/jslrt.24061
ライセンス
https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ja
助成機関名
Japan Society for the Promotion of Science
MHLW
Japan Agency for Medical Research and Development
Ryobi Teien Memory Foundation
助成番号
JP 23K1447605
24KK0172
JPMH 23FC1025
JP 22ek0109589h0001